drugset / Trial / NCT04465890
A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients
Phase 2
Completed
207 enrolled
Ascletis Pharmaceuticals Co., Ltd.
Beijing Clinical Service Center · collabPeking University First Hospital · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The objective of this study is to evaluate the safety and efficacy of ASC22 in the treatment of chronic hepatitis B after single and multiple drug administration.
Timeline
- Start
- 2020-07-17
- Primary completion
- 2024-08-09
- Completion
- 2024-08-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Envafolimab | Monoclonal antibody | 0.3 mg/kg | Subcutaneous |
| Subject | Envafolimab | Monoclonal antibody | 1 mg/kg | Subcutaneous |
| Subject | Envafolimab | Monoclonal antibody | 2.5 mg/kg | Subcutaneous |